X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (274) 274
Book Review (38) 38
Publication (38) 38
Book / eBook (10) 10
Book Chapter (5) 5
Dissertation (5) 5
Newspaper Article (3) 3
Conference Proceeding (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (217) 217
humans (209) 209
female (158) 158
oncology (153) 153
breast neoplasms - drug therapy (98) 98
breast cancer (83) 83
middle aged (64) 64
aged (57) 57
adult (54) 54
chemotherapy (50) 50
breast neoplasms - pathology (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
cancer (45) 45
breast neoplasms - genetics (39) 39
article (31) 31
therapy (30) 30
antineoplastic agents - therapeutic use (29) 29
breast neoplasms - mortality (29) 29
prognosis (29) 29
trastuzumab (29) 29
hematology, oncology and palliative medicine (28) 28
animals (27) 27
medicine & public health (27) 27
abridged index medicus (26) 26
obstetrics and gynecology (25) 25
breast neoplasms - therapy (24) 24
disease-free survival (24) 24
treatment outcome (23) 23
women (23) 23
chemotherapy, adjuvant (22) 22
research (22) 22
breast neoplasms - metabolism (21) 21
neoplasm metastasis (21) 21
analysis (20) 20
metastasis (20) 20
randomized controlled trials as topic (20) 20
care and treatment (19) 19
male (19) 19
neoplasm staging (19) 19
survival (19) 19
clinical trials (18) 18
endothelial growth-factor (18) 18
paclitaxel - administration & dosage (18) 18
tumors (18) 18
antibodies, monoclonal, humanized (17) 17
clinical trials as topic (17) 17
expression (17) 17
risk factors (17) 17
mice (16) 16
angiogenesis (15) 15
doxorubicin - administration & dosage (15) 15
drug therapy (15) 15
gene expression (15) 15
gene-expression (15) 15
risk (15) 15
tamoxifen (15) 15
united states (15) 15
aged, 80 and over (14) 14
breast neoplasms - surgery (14) 14
cell line, tumor (14) 14
paclitaxel (14) 14
breast neoplasms - diagnosis (13) 13
carcinoma (13) 13
health aspects (13) 13
kaplan-meier estimate (13) 13
receptor, erbb-2 - metabolism (13) 13
tumor cells, cultured (13) 13
antibodies, monoclonal - therapeutic use (12) 12
breast neoplasms (12) 12
diagnosis (12) 12
drug administration schedule (12) 12
gene expression profiling (12) 12
surgery (12) 12
womens health (12) 12
antineoplastic agents - pharmacology (11) 11
bevacizumab (11) 11
cyclophosphamide - administration & dosage (11) 11
gene expression regulation, neoplastic (11) 11
medical research (11) 11
recurrence (11) 11
time factors (11) 11
adjuvant chemotherapy (10) 10
antineoplastic agents, hormonal - therapeutic use (10) 10
breast-cancer (10) 10
cells (10) 10
docetaxel (10) 10
genetic aspects (10) 10
medicine, general & internal (10) 10
survival rate (10) 10
trial (10) 10
angiogenesis inhibitors - therapeutic use (9) 9
breast (9) 9
breast neoplasms - enzymology (9) 9
doxorubicin (9) 9
genes (9) 9
genomics (9) 9
growth (9) 9
mastectomy (9) 9
patients (9) 9
proportional hazards models (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1999, Hematology/oncology clinics of North America, Volume 13, no. 2., x, p. 311-475
Book
2012, ISBN 1846920663, 176
Book
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 04/2017, Volume 35, Issue 10, pp. 1031 - 1031
Journal Article
Cancer Research, ISSN 0008-5472, 04/2001, Volume 61, Issue 8, pp. 3369 - 3372
Journal Article
Journal of Oncology Practice, ISSN 1554-7477, 06/2018, Volume 14, Issue 6, pp. 357 - 358
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2018, Volume 379, Issue 2, pp. 111 - 121
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 05/2013, Volume 105, Issue 10, pp. 701 - 710
Journal Article
Journal Article
BMC Cancer, ISSN 1471-2407, 11/2013, Volume 13, Issue 1, pp. 537 - 537
Background: Triple Negative subset of (TN) Breast Cancers (BC), a close associate of the basal-like subtype (with limited discordance) is an aggressive form of... 
Breast cancer | Microarray | Wnt | FFPE | Triple negative | GENE-EXPRESSION SIGNATURE | ANDROGEN RECEPTOR | REGULATES EXPRESSION | SUBTYPES | T-CELL-FACTOR | BETA-CATENIN | MESENCHYMAL TRANSITION | ONCOLOGY | PATHWAY | COLORECTAL-CANCER | BASAL | RNA, Small Interfering - genetics | Cell Proliferation | Prognosis | Follow-Up Studies | Oligonucleotide Array Sequence Analysis | Humans | Lung Neoplasms - metabolism | Gene Expression Regulation, Neoplastic | Bone Neoplasms - secondary | Gene Expression Profiling | Wnt Proteins - metabolism | Brain Neoplasms - metabolism | Immunoenzyme Techniques | Bone Neoplasms - metabolism | Neoplasm Recurrence, Local - pathology | Paraffin Embedding | Brain Neoplasms - secondary | Wnt Proteins - genetics | Lung Neoplasms - secondary | Triple Negative Breast Neoplasms - pathology | Biomarkers, Tumor - metabolism | Female | Bone Neoplasms - genetics | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Lung Neoplasms - genetics | Neoplasm Recurrence, Local - metabolism | Signal Transduction | RNA, Messenger - genetics | Brain Neoplasms - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | beta Catenin - metabolism | Blotting, Western | beta Catenin - genetics | Triple Negative Breast Neoplasms - genetics | Triple Negative Breast Neoplasms - metabolism | beta Catenin - antagonists & inhibitors | Neoplasm Recurrence, Local - genetics | Biomarkers, Tumor - genetics | Neoplasm Staging | Cell Movement | Cohort Studies | Research | Metastasis | Biological markers | Analysis | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Cancer, ISSN 0008-543X, 05/2000, Volume 88, Issue 9, pp. 2047 - 2053
Raloxifene HCl (150 mg administered twice daily) demonstrated low toxicity and modest antitumor activity in postmenopausal women with metastatic or... 
selective estrogen receptor modulator (SERM) | endocrine treatment | antiestrogen | postmenopausal women | breast carcinoma | Breast | raloxifene | Breast carcinoma | Postmenopausal women | Raloxifene | Endocrine treatment | Antiestrogen | Selective estrogen receptor modulator (SERM) | ANTIESTROGENS | BONE-MINERAL DENSITY | FUNCTIONAL ASSESSMENT | TAMOXIFEN | PHASE-III | SURGICAL-ADJUVANT-BREAST | CANCER | THERAPY | ONCOLOGY | CARDIOVASCULAR RISK-FACTORS | Raloxifene Hydrochloride - adverse effects | Confidence Intervals | Raloxifene Hydrochloride - therapeutic use | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Selective Estrogen Receptor Modulators - adverse effects | Tamoxifen - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Selective Estrogen Receptor Modulators - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Postmenopause | Adult | Female | Safety | Carcinoma - secondary | Carcinoma - drug therapy | Antineoplastic Agents, Hormonal - administration & dosage | Receptors, Estrogen - antagonists & inhibitors | Selective Estrogen Receptor Modulators - administration & dosage | Survival Rate | Breast Neoplasms - drug therapy | Remission Induction | Disease Progression | Estrogen Antagonists - administration & dosage | Estrogen Antagonists - therapeutic use | Raloxifene Hydrochloride - administration & dosage | Tamoxifen - therapeutic use | Estrogen Antagonists - adverse effects | Quality of Life | Aged | Neoplasm Staging | Evaluation | Breast cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2012, Volume 30, Issue 2, pp. 203 - 209
Journal Article